Status: Recruiting
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with respect to the standard of care (surgery and adjuvant therapy).
Participants needed: 186
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Philogen S.p.A.Updated: Dec 17, 2025Locations: 37
Eligibility criteria
Histologically or cytologically confirmed diagnosis of clinical stage IIIB, IIIC... [+18]
Uveal melanoma or mucosal melanoma [+21]